Position in DNLI
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$5,510,400
+$772,014 QoQ
Shares Held
287,000
-0.0% QoQ
Ownership
0.181%
of shares outstanding
% of Portfolio
0.06%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Marex Group plc holds $67,253,480 across 58 Biotechnology names. DNLI ranks #5 (8.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | SANA |
Sana Biotechnology, Inc.
|
3,999,100 | $11,517,408 | |
| 2 | TGTX |
Tg Therapeutics, Inc.
|
278,343 | $9,246,553 | |
| 3 | NTLA |
Intellia Therapeutics, Inc.
|
623,600 | $7,994,552 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
134,097 | $6,378,994 | |
| 5 | DNLI |
Denali Therapeutics Inc.
This page
|
287,000 | $5,510,400 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
7,368 | $3,290,106 | |
| 7 | MRNA |
Moderna, Inc.
|
63,622 | $3,231,997 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,739 | $1,343,620 |
All Filings in DNLI
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $5,510,400 | 287,000 | Shares | Defined | 2026-05-13 | |
| 2025-12-31 | $4,738,386 | 287,001 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $4,225,320 | 291,000 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $3,665,380 | 262,000 | Shares | Defined | 2025-08-19 | |
| No filing history on record for this holder in this stock. | ||||||